Summary of Purpose
Botulinum toxin A (GSK1358820) is a sterile, purified type A botulinum neurotoxin complex. In Japan, 240 units of botulinum toxin A are approved as a maximum dose per administration for upper limb spasticity. This study is planned to evaluate the effectiveness and safety of 400 units of botulinum toxin A which can help to increase the maximum dose per administration to 400 units from 240 units as the treatment...Read More →
The following dates are available for this trial. Trial information last updated on 9 February 2018.
|2 Aug 2017||23 Aug 2017||28 Jan 2019||28 Feb 2019||1 Feb 2018||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- GlaxoSmithKline Lead
- US GSK Clinical Trials Call Center